JP2016504401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504401A5 JP2016504401A5 JP2015552092A JP2015552092A JP2016504401A5 JP 2016504401 A5 JP2016504401 A5 JP 2016504401A5 JP 2015552092 A JP2015552092 A JP 2015552092A JP 2015552092 A JP2015552092 A JP 2015552092A JP 2016504401 A5 JP2016504401 A5 JP 2016504401A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- pain
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229920000642 polymer Polymers 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 229920001451 polypropylene glycol Polymers 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- -1 PEG500 Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940116364 hard fat Drugs 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- 108010087765 Antipain Proteins 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000006255 nuclear receptors Human genes 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752356P | 2013-01-14 | 2013-01-14 | |
| US61/752,356 | 2013-01-14 | ||
| PCT/EP2014/050628 WO2014108569A1 (en) | 2013-01-14 | 2014-01-14 | Compositions and methods for treating severe pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504401A JP2016504401A (ja) | 2016-02-12 |
| JP2016504401A5 true JP2016504401A5 (enExample) | 2017-02-16 |
| JP6474732B2 JP6474732B2 (ja) | 2019-02-27 |
Family
ID=50064547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552092A Active JP6474732B2 (ja) | 2013-01-14 | 2014-01-14 | 激痛治療用組成物と方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2943183A1 (enExample) |
| JP (1) | JP6474732B2 (enExample) |
| KR (1) | KR20150129665A (enExample) |
| CN (1) | CN104968330A (enExample) |
| AU (1) | AU2014204739B2 (enExample) |
| BR (1) | BR112015015864B1 (enExample) |
| CA (1) | CA2897874A1 (enExample) |
| HK (1) | HK1217650A1 (enExample) |
| IL (1) | IL239921A0 (enExample) |
| MX (1) | MX2015009045A (enExample) |
| RU (1) | RU2677346C2 (enExample) |
| SG (1) | SG11201505245XA (enExample) |
| WO (1) | WO2014108569A1 (enExample) |
| ZA (1) | ZA201505005B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| WO2018027001A1 (en) * | 2016-08-03 | 2018-02-08 | Temple University-Of The Commonwealth System Of Higher Education | Microencapsulation of active agents |
| JP7027786B2 (ja) * | 2017-10-12 | 2022-03-02 | ライオン株式会社 | 筋・筋膜性疼痛用の内服治療剤 |
| CA3212583A1 (en) | 2021-03-27 | 2022-10-06 | Daniel Gooding | Compositions having improved bioavailability of therapeutics |
| CN116660550B (zh) * | 2023-06-19 | 2024-08-13 | 南通大学 | 一种dgat2的抑制剂pf-06424439用于缓解疼痛的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
| GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| KR100509776B1 (ko) * | 1997-07-29 | 2005-08-24 | 파마시아 앤드 업존 캄파니 엘엘씨 | 친지성 화합물의 자가유화 제제 |
| US6231887B1 (en) * | 1997-07-29 | 2001-05-15 | Pharmacia & Upjohn Company | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| WO2000067728A2 (de) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Lipidpartikel auf der basis von mischungen von flüssigen und festen lipiden und verfahren zu ihrer herstellung |
| KR20020011985A (ko) * | 1999-05-07 | 2002-02-09 | 파르마솔 게엠베하 | 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법 |
| RU2246293C2 (ru) * | 1999-06-14 | 2005-02-20 | Космо С.П.А. | Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом |
| US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
| JP2002284705A (ja) * | 2001-01-19 | 2002-10-03 | Shiseido Co Ltd | 刺激緩和剤 |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| US20070298099A1 (en) * | 2004-11-24 | 2007-12-27 | Peresypkin Andrey V | Liquid and Semi-Solid Pharmaceutical Formulations for Oral Administration of a Substituted Amide |
| JP2008539230A (ja) * | 2005-04-28 | 2008-11-13 | ガレニカ テクノロジー アンチエボラグ | 脂質相を含む薬学的投与形態 |
| GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| EP2310371B1 (fr) | 2008-05-26 | 2013-05-15 | Genfit | Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies |
| CN102048680B (zh) * | 2009-11-11 | 2013-05-01 | 河北奥星集团药业有限公司 | 一种含有扎托布洛芬的肠溶缓释制剂及其制备方法 |
| RU2016138830A (ru) * | 2011-02-04 | 2018-12-12 | ИнФёрст Хэлткэр Лимитед | Составы и способы для лечения сердечно-сосудистых заболеваний |
| CN102579350B (zh) * | 2012-03-02 | 2013-04-24 | 海南灵康制药有限公司 | 右旋布洛芬脂质体固体制剂 |
-
2014
- 2014-01-14 EP EP14702759.3A patent/EP2943183A1/en not_active Withdrawn
- 2014-01-14 SG SG11201505245XA patent/SG11201505245XA/en unknown
- 2014-01-14 CN CN201480006249.1A patent/CN104968330A/zh active Pending
- 2014-01-14 KR KR1020157020599A patent/KR20150129665A/ko not_active Withdrawn
- 2014-01-14 HK HK16105731.5A patent/HK1217650A1/zh unknown
- 2014-01-14 WO PCT/EP2014/050628 patent/WO2014108569A1/en not_active Ceased
- 2014-01-14 MX MX2015009045A patent/MX2015009045A/es unknown
- 2014-01-14 RU RU2015134136A patent/RU2677346C2/ru active IP Right Revival
- 2014-01-14 JP JP2015552092A patent/JP6474732B2/ja active Active
- 2014-01-14 CA CA2897874A patent/CA2897874A1/en not_active Abandoned
- 2014-01-14 AU AU2014204739A patent/AU2014204739B2/en active Active
- 2014-01-14 BR BR112015015864-1A patent/BR112015015864B1/pt active IP Right Grant
-
2015
- 2015-07-13 ZA ZA2015/05005A patent/ZA201505005B/en unknown
- 2015-07-14 IL IL239921A patent/IL239921A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504401A5 (enExample) | ||
| JP2016506941A5 (enExample) | ||
| JP2016504403A5 (enExample) | ||
| JP2018526351A5 (enExample) | ||
| JP2016508155A5 (enExample) | ||
| CL2015001257A1 (es) | Compuestos derivados de 3-(3-(3,5-bis(trifluorometil)fenil)-1h-1,2,4-triazol-1-il)-hidrazida; composicion farmaceutica; procedimiento para preprar precursores; procedimiento para tratar; uso para tratar trastornos asociados a crm1 tal como trastorno proliferativo, inflamatorio, entre otros (divisional de solicitud n° 225-2014). | |
| EP3355874A4 (en) | TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| EA201891120A1 (ru) | 1,3-тиазол-2-ил замещенные бензамиды | |
| JP2016505625A5 (enExample) | ||
| JP2014114295A5 (enExample) | ||
| HRP20220075T1 (hr) | Tekuća formulacija koja sadrži nikotin za aerosolnu primjenu | |
| EA201790202A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| RU2015134136A (ru) | Композиции и способы для лечения сильной боли | |
| EA201591686A1 (ru) | Пиридинильные и конденсированные пиридинильные производные триазолона | |
| JP2014218522A5 (enExample) | ||
| MX387217B (es) | Composiciones de solución sólida para aines. | |
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
| JP2018537513A5 (enExample) | ||
| AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco | |
| WO2015150449A3 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 |